Company is pioneering a novel approach by targeting fibrotic mediators that drive disease progression Portfolio comprises three targets, each of which is measurable in plasma and correlates with disease severity Proceeds will advance programs into clinical studies in 2024; Lead asset…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.